Home » Stocks » OTIC

Otonomy, Inc. (OTIC)

Stock Price: $4.57 USD 0.27 (6.28%)
Updated November 27, 12:46 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 220.40M
Revenue (ttm) 313,000
Net Income (ttm) -45.01M
Shares Out 48.23M
EPS (ttm) -1.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $4.57
Previous Close $4.30
Change ($) 0.27
Change (%) 6.28%
Day's Open 4.29
Day's Range 4.26 - 4.63
Day's Volume 157,719
52-Week Range 1.53 - 4.89

More Stats

Market Cap 220.40M
Enterprise Value 157.83M
Earnings Date (est) Mar 8, 2021
Ex-Dividend Date n/a
Shares Outstanding 48.23M
Float 43.73M
EPS (basic) -1.32
EPS (diluted) -1.27
FCF / Share -0.78
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 620,893
Short Ratio 3.52
Short % of Float 1.42%
Beta 2.16
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 704.16
PB Ratio 2.81
Revenue 313,000
Operating Income -44.04M
Net Income -45.01M
Free Cash Flow -38.38M
Net Cash 62.57M
Net Cash / Share 1.30
Gross Margin -99.68%
Operating Margin -14,070.93%
Profit Margin -14,379.90%
FCF Margin -12,261.98%
ROA -26.55%
ROE -71.59%
ROIC -64.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$10.00*
(118.82% upside)
Low
9.00
Current: $4.57
High
11.00
Target: 10.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue0.600.751.240.68----
Revenue Growth-19.46%-39.72%80.97%-----
Gross Profit-0.31-0.20-1.86-0.98----
Operating Income-44.81-52.05-91.40-111-61.98-39.64-19.85-10.93
Net Income-44.68-50.37-90.13-111-61.67-42.88-19.56-7.57
Shares Outstanding30.7330.6130.3029.9623.957.850.070.07
Earnings Per Share-1.45-1.65-2.97-3.69-2.57-5.46-268.79-118.99
Operating Cash Flow-36.93-38.43-75.31-94.31-49.90-35.22-19.47-10.83
Capital Expenditures-0.70-0.50-1.26-2.55-2.02-0.78-0.49-0.19
Free Cash Flow-37.63-38.93-76.57-96.85-51.92-36.00-19.95-11.01
Cash & Equivalents61.3797.9812119718615637.364.71
Total Debt33.5914.76-----7.07
Net Cash / Debt27.7883.2212119718615637.36-2.35
Assets83.0210512820919315939.765.90
Liabilities42.7925.2611.0915.8611.505.553.5811.92
Book Value40.2379.74117193182154-58.98-39.07
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Otonomy, Inc.
Country United States
Employees 49
CEO David A. Weber

Stock Information

Ticker Symbol OTIC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: OTIC
IPO Date August 13, 2014

Description

Otonomy, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.